Temat: ezetimibe - Katalog OPAC zbiorów

Skocz do pozycji: 1.

Tytuł:: Ezetimibe prevents myocardial remodeling in an obese rat model by inhibiting inflammation
Autorzy:: Li, Xiao-Xing
Zhao, Lang
Chang, Ying
Liu, Bao-Shan
Xu, Feng
Zhang, Cheng
Ji, Xiao-Ping
Chen, Yu-Guo
Li, Chuan-Bao
Powiązania:: https://bibliotekanauki.pl/articles/1038380.pdf
Data publikacji:: 2018
Wydawca:: Polskie Towarzystwo Biochemiczne
Tematy:: obese
inflammation
remodeling
ezetimibe
IL-6
Opis:: Inflammation plays an important role in the development of many obesity-related diseases. This study aimed to investigate the effect of ezetimibe on inflammation and myocardial remodeling in obese rats. A rat model of obesity was established, and myocardial damage was examined by transmission electron microscopy and Masson staining. Twenty obese rats were divided into two groups (n=10): obese group and ezetimibe group. Ten SD rats were used as controls. Western blot was performed to monitor the expression of P-p38MAPK and interleukin (IL)-6. Immunohistochemical staining was used to monitor the expression of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1. In the obese rats group, we observed increased inflammatory factors and myocardial hypertrophy. In contrast, the ezetimibe group exhibited decreased expression of inflammatory factors and an improvement in myocardial remodeling compared to the obese group. Mechanistically, we found that ezetimibe decreased P-p38MAPK, IL-6, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 levels in the hearts of the obese rats. Taken together, these results indicate that ezetimibe may improve myocardial remodeling in obese rats by inhibiting inflammation.
Źródło:: Acta Biochimica Polonica; 2018, 65, 3; 465-470
0001-527X
Pojawia się w:: Acta Biochimica Polonica
Dostawca treści:: Biblioteka Nauki

Artykuł

Zmień widok

na półce

Skocz do pozycji: 2.

Tytuł:: Połączenie atorwastatyny i ezetymibu w terapii hipercholesterolemii
Autorzy:: Pęksa, Jan
Powiązania:: https://bibliotekanauki.pl/articles/2080187.pdf
Data publikacji:: 2022-06-22
Wydawca:: Wydawnictwo Naukowe Medyk sp. z o.o.
Tematy:: atorvastatin
ezetimibe
cardiovascular risk
chronic coronary syndromes
atorwastatyna
ezetymib
ryzyko sercowo-naczyniowe
przewlekłe zespoły wieńcowe
Opis:: Cardiovascular (CV) diseases are still the leading cause of death in Poland. In treatment of hypercholesterolemia, HMG-CoA reductase inhibitors (statins) are the first-line drugs with proven beneficial effect on patient prognosis. These drugs include one of the two potent statins, atorvastatin. If the target level of LDL cholesterol is not achieved despite lifestyle changes and statin therapy, a drug with a different mechanism of action, e.g. ezetimibe, is added to the treatment. In this way a greater hypolipemic effect is achieved. Single pill combinations (SPC) containing two active substances in one tablet are a good choice. Indications for therapy with SPC preparations with statins and ezetimibe include therapy for primary hypercholesterolemia, mixed hyperlipidemia, heterozygous and homozygous familial hypercholesterolemia, and prevention of CV events in patients at increased risk for these incidents. SPC drug is used to control hypercholesterolemia with atorvastatin and ezetimibe as separate formulations, at the same doses as in the combination formulation. SPC formulations containing 10 mg of ezetimibe in combination with 10 or, 20, or 40 or 80 mg of atorvastatin are available on the Polish pharmaceutical market.
Źródło:: Gabinet Prywatny; 2022, 282, 03; 5-13
2353-8600
Pojawia się w:: Gabinet Prywatny
Dostawca treści:: Biblioteka Nauki

Artykuł

Zmień widok

na półce

Skocz do pozycji: 3.

Tytuł:: Atorwastatyna i ezetymib – skuteczne połączenie w terapii dyslipidemii
Atorvastatin and ezetimibe – effective combination therapy for dyslipidemia
Autorzy:: Pęksa, Jan W.
Powiązania:: https://bibliotekanauki.pl/articles/2138887.pdf
Data publikacji:: 2022-04-01
Wydawca:: Wydawnictwo Naukowe Medyk sp. z o.o.
Tematy:: atorvastatin
ezetimibe
cardiovascular risk
chronic coronary syndromes
combination therapy
atorwastatyna
ezetymib
ryzyko sercowo-naczyniowe
przewlekłe zespoły wieńcowe
terapia złożona
Opis:: A good therapeutic option in hypercholesterolemia is the use of combination preparations containing an HMG-CoA reductase inhibitor, such as atorvastatin, and a drug that selectively inhibits the absorption of holesterol and plant sterol derivatives from the gut - ezetimibe - in a single tablet. Such treatment can be implemented in adults with primary hypercholesterolemia, familial hypercholesterolemia or mixed hyperlipidemia, which is already controlled with atorvastatin and ezetimibe as separate preparations, at the same doses as in the combination preparation. The preparation is administered 1x /day at any time, day. It is mostly a safe drug and well tolerated by patients. Possible side effects are mainly due to possible side effects of statins.
Źródło:: Gabinet Prywatny; 2022, 284, 04; 7-12
2353-8600
Pojawia się w:: Gabinet Prywatny
Dostawca treści:: Biblioteka Nauki

Artykuł

Zmień widok

na półce

Informacja

Wyszukujesz frazę "ezetimibe" wg kryterium: Temat

Źródło danych

Dostawca treści

Kolekcja

Rok wydania

Wydawca

Temat

Autor

Typ dokumentu

Język